Xilio Therapeutics (XLO) EBIT (2020 - 2026)

Xilio Therapeutics has disclosed EBIT across 7 years of filings, most recently posting -$14.1 million for Q1 2026.

• EBIT for Q1 2026 came in at -$14.1 million, down 1.88% year-over-year; the trailing twelve-month figure through Mar 2026 was -$42.2 million (up 25.82% YoY), and the FY2025 annual result was -$42.0 million, up 30.7% from the prior year.
• EBIT came in at -$14.1 million for Q1 2026 at Xilio Therapeutics, down from -$11.8 million in the prior quarter.
• In the past five years, EBIT ranged from a high of -$1.9 million in Q3 2025 to a low of -$24.6 million in Q2 2022.
• The 5-year median for EBIT is -$17.4 million (2023), against an average of -$16.8 million.
• Across the five-year window, EBIT decreased 28.47% in 2022 and surged 86.93% in 2025, its largest moves.
• Xilio Therapeutics' EBIT stood at -$23.2 million in 2022, then grew by 21.74% to -$18.1 million in 2023, then rose by 24.83% to -$13.6 million in 2024, then rose by 13.16% to -$11.8 million in 2025, then slipped by 19.23% to -$14.1 million in 2026.
• The last three EBIT figures came in at -$14.1 million (Q1 2026), -$11.8 million (Q4 2025), and -$1.9 million (Q3 2025), per Business Quant data.